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Abstract 
Metabolic syndrome plays a vital role in present-day primary care. The ICD-10 diagnostic 
coding for this set of symptoms more comprehensively identifies patients with increased risk of 
cardiovascular events and comorbidities. Metabolic syndrome affects one-third of adults in the 
US and is defined as the presence of three of the following characteristics: abdominal obesity, 
hypertension, elevated triglycerides, low high-density lipoprotein, and elevated fasting plasma 
glucose. Proper screening for metabolic syndrome can identify complex patients before 
conditions like hypertension or type II diabetes develop. Management of metabolic syndrome 
emphasizes prevention and prioritizes lifestyle modifications as first-line treatment. Despite 
strong evidence supporting the use of metabolic syndrome as a key diagnostic code, it is not 
being routinely identified and documented in primary care.  Moreover, without proper screening, 
identification, and coding for metabolic syndrome in primary care, management and lifestyle 
modifications may not be initiated in a timely way or at all. This shows evidence of the large gap 
between what we know about metabolic syndrome and how to identify it and what is actually 
happening in primary care. Purpose: To address this gap, a DNP project was implemented at 
two primary care sites. Its purpose was to increase primary care provider knowledge, 
identification, and ICD-10 coding of metabolic syndrome, leading to better office visit follow-up 
and enhanced patient outcomes. Toolkit: A toolkit was developed based on the 2009 American 
College of Preventive Medicine Metabolic Syndrome Time Tool and accompanying verbal 
presentation with a PowerPoint. The intervention was provided live at two primary care sites to 
healthcare staff, including providers (NP, PA, MD) and nurses (RN, LPN). Outcomes: Valuable 
data were obtained regarding enhancement of provider knowledge and perceptions of metabolic 
syndrome, as well as their engagement with and use of the toolkit. Conclusion: Use of metabolic 
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syndrome as a key ICD code is supported by strong evidence, primary care providers are 
amenable to its use, yet remain slow to adapt it into their medical records systems. Further 
investigation in this area is needed. 
Keywords: metabolic syndrome, abdominal obesity, American College of Preventive Medicine, 
atherosclerotic disease, elevated fasting plasma glucose level, elevated triglycerides, exercise, 
hypertension, lifestyle management, low HDL, type II diabetes, Metabolic Syndrome Time Tool, 
primary care, toolkit
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Background and Evidence of Problem 
This paper chronicles a Doctor of Nursing Practice (DNP) Project regarding metabolic 
syndrome identification in the primary care setting. Over time investigative work toward 
defining metabolic syndrome has been driven by healthcare providers trying to understand the 
effect and impact of a cluster of frequently occurring coexistent physical characteristics on 
patients’ increased risks for cardiovascular disease and diabetes (Meisinger, Koletzko, & 
Heinrich, 2006; Sarafidis & Nilsson, 2006). Metabolic syndrome is a serious health problem and 
primary care providers should include metabolic syndrome in primary care.  
Almost a century ago, scientists began to describe the common coexistence of various 
components of metabolic syndrome. In 1923, Eskil Kylin described the clustering of 
hypertension, hyperglycemia, and gout. In 1947, French physician Dr. Jean Vague reported that 
upper body obesity is often associated with certain metabolic abnormalities. In 1975, Hermann 
Haller introduced the term metabolic syndrome (Haller & Hanefeld, 1975). Modern recognition 
of  metabolic syndrome began in the 1980s with Dr. Gerald Reaven and continued into the 1990s 
as large organization such as the World Health Organization became involved (Alberti & 
Zimmet, 1998; Reaven 1988; 2005). Subsequently, in 2001, the Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) developed the current 
definition of metabolic syndrome.  
Over the past two decades, many organizations have developed definitions and guidelines 
to manage metabolic syndrome, including the American College of Cardiology, American Heart 
Association (AHA) and National Heart Lung Blood Institute (NHLBI), American Diabetes 
Association (ADA), and International Diabetes Federation (IDF). At present, there are two most 
widely accepted definitions from the AHA/NHLBI ATP III Update and the IDF. However, there 
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have not been new updates to existing guidelines since 2005 – 2009, depending on the 
organization.  
Metabolic syndrome is an aggregate of physical characteristics and risk factors that 
greatly affect health and quality of life yet can be preventable. Metabolic syndrome encapsulates 
many comorbidities and complications, related to the individual characteristics and diseases 
making up the syndrome. The five characteristics of metabolic syndrome include abdominal 
obesity, hypertension, elevated triglycerides, reduced HDL cholesterol, and elevated fasting 
plasma glucose level (Ervin, 2009; Grundy et al., 2005; IDF, 2006; Mallory, Angosta, & Kawi, 
2014; National Health Institute (NIH), 2004).  
One third of adults in the US and one quarter of adults in the world have metabolic 
syndrome (IDF, 2006; Mozumdar & Liguori, 2011). The risk of metabolic syndrome increases 
most significantly with obesity, which is apparent when comparing the prevalence of metabolic 
syndrome to a rise in obesity rates (AHA, 2014; Ervin, 2009). In fact, the increase in obesity rate 
is occurring despite mounting awareness of the condition and efforts to prevent or treat those at 
risk or affected by the syndrome. Additionally, abdominal obesity has been shown to have more 
complications than lower body fat because of the proximity of fat cells to the liver, which plays 
important roles in metabolism (Ferranti & Mozaffarian, 2008) .  
There are many comorbidities and complications associated with metabolic syndrome. 
These can be identified looking at metabolic syndrome as a whole, as well as the known 
outcomes of the individual characteristics. These characteristics, diseases, comorbidities, and 
complications create a complex, interconnected web of body systems problems. For example, 
elevated fasting plasma glucose is one characteristic of metabolic syndrome and if it progresses 
to diabetes, comorbidities and complications may include heart disease, stroke, kidney failure, 
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blindness, neuropathy, and digit or limb amputation (Caro, Ward, & O’Brien, 2002; Centers for 
Disease Control and Prevention [CDC], 2014). Furthermore, abdominal obesity is a risk factor 
for cardiovascular disease and hyperlipidemia is a risk factor for heart attack, stroke, heart 
disease, coronary artery disease, and peripheral vascular disease (Fiegal, Kit, Orpana, & 
Graubard, 2013; National Cholesterol Education Program [NCEP], 2002). Hypertension 
complications include heart failure, left ventricular hypertrophy, ischemic stroke, intracerebral 
hemorrhage, heart disease, myocardial infarction, chronic kidney disease, and end-stage renal 
disease (Egan, Zhao, & Axon, 2010). Low HDL is a biomarker inversely related with 
cardiovascular disease and coronary heart disease (Mackey et al., 2012). As a result, any 
complications, combined or individual, can have detrimental effects on patient’s well-being.   
Due to the aforementioned characteristics of metabolic syndrome such as hypertension, 
obesity, and diabetes, metabolic syndrome has significant societal and financial implications. 
According to the CDC (2014), the estimated annual medical cost of the total direct and indirect 
costs of diabetes during 2012 was $254 billion. The annual medical cost of obesity is estimated 
at $147 billion. In 2011, total cost associated with hypertension was $46 billion (CDC, 2013). 
These staggering annual medical costs will continue to increase with the increased prevalence of 
metabolic syndrome.  
Age, race, and weight are the most influential factors for developing metabolic syndrome  
(IDF, 2006; Park et al., 2013). Those at highest risk include individuals that are obese, Mexican-
American, or women. Other risk factors include postmenopausal status, smoking, low household 
income, high carbohydrate diet, and physical inactivity. All of these risk factors can be managed 
in primary care. Many patients are identified with individual characteristics of metabolic 
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syndrome such as obesity or hypertension but often times, metabolic syndrome is not identified 
as a primary diagnosis, which may result in inadequate treatment interventions (ACPM, 2009).  
Successful diagnosis of metabolic syndrome can lead to better treatment and improved quality of 
life, therefore limiting complications and decreasing or eliminating preventable healthcare costs 
(AHA, 2014).  
Problem Statement 
Risk of metabolic syndrome among adults is increasing, both locally and globally, and it 
affects an estimated one third of adults in the US. An extensive review of the literature revealed 
that although the prevalence of metabolic syndrome is high when a population is screened, those 
percentages were based on individual studies’ or organizations’ assessment of a population, not 
the presence of a metabolic syndrome diagnosis coded by a primary care provider (ACPM, 
2009). This led the DNP student to understand that metabolic syndrome identification and 
documentation are not widely used in primary care. It was speculated that metabolic syndrome is 
being under-coded and thus under-recognized. Adequately identifying patients with metabolic 
syndrome is the first step to clinically addressing this complex problem. 
Review of the Literature  
The focus of this review of literature was on the metabolic syndrome definition, 
management, and use of International Classification of Diseases (ICD) coding. An extensive 
review, including the journal Metabolic Syndrome and Related Disorders (2015), revealed 
hundreds of articles identifying research related to the pathophysiology and extensive effects of 
metabolic syndrome. This search yielded over 15,000 articles and guidelines. Inclusion criteria 
consisted of peer reviewed, full-text articles published in the English language within the past ten 
years, concerning adults greater than eighteen years old. Based on title and abstract, the results 
IDENTIFYING PATIENTS WITH METABOLIC SYNDROME 8 
were further narrowed down to forty-five. After further review of each text, thirteen articles 
published from 2002 – 2014 were retained.  
There are numerous practice guidelines related to the management of metabolic 
syndrome, however many of these guidelines are dated based on preferred standards for evidence 
based research. Additionally, based on the review of the literature, it was noted that there is a 
significant amount of information known about metabolic syndrome but not effective application 
of metabolic syndrome as a diagnostic code in primary care; as demonstrated by the fact that 
providers are not routinely identifying or documenting metabolic syndrome. Moreover, the 
search did not yield even one reviewed article where the authors utilized existing data on patients 
with metabolic syndrome in a primary care practice. Hence, the review of the literature 
demonstrated a gap in the diagnosis and identification of metabolic syndrome.  
There were two highlights from this review of literature, including the American Heart 
Association/National Heart, Lung, and Blood Institute Scientific Statement from 2005 that used 
the Adult Treatment Panel III’s 2002 metabolic syndrome definition. This guideline is favored 
because of the ease of use in the primary care setting and focus on lifestyle management. The 
second highlight was the American College of Preventive Medicine’s (ACPM) Metabolic 
Syndrome Time Tool. This is an important guide in the diagnosis and treatment of metabolic 
syndrome, as it was identified in the literature review as the most thorough and evidence based 
resource for this DNP Project.  
The most current guidelines and recommendations come from the 2005 AHA/NHLBI 
Diagnosis and Management of the Metabolic Syndrome (Grundy et al., 2005) and the 2006 
International Diabetes Foundation Consensus Worldwide Definition of the Metabolic Syndrome. 
The AHA/NHLBI Management of the Metabolic Syndrome is an update of the 2002 Adult 
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Treatment Panel III (ATP III) Guidelines from the National Cholesterol Education Program 
(NCEP, 2002). The updated 2005 ATP III criteria were used in the presentation and toolkit due 
to their vast acceptance, ease of application and use in the clinic setting. In 2009, the Metabolic 
Syndrome Time Tool was released based on the ATP III and a synthesis of the most up-to-date 
information at the time.  
The Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at 
Metabolic Risk, an Endocrine Society Clinical Practice Guidelines also provides guidelines for 
managing metabolic risk (Rosenzweig et al., 2008). This guideline provides similar information 
to the IDF (2006), ATP III (2002), and AHA/NHLBI (2005) release. Guidelines that further 
influenced the Metabolic Syndrome Time Tool (American College of Preventive Medicine 
[ACPM], 2009) include the Physical Activity Guideline from the American College of Sports 
Medicine and the AHA, Treatment of Metabolic Syndrome from the Finnish Medical Society, 
and Screening for Metabolic Syndrome in Adults–University of Texas at Austin, Family Nurse 
Practitioner Program, and Diet Guideline from the U.S. Preventive Services Task Force.   
There is little controversy or discourse in suggestions for the management of metabolic 
syndrome between the guidelines. All guidelines recommend early diagnosis, regular screening, 
and lifestyle therapy as the primary intervention. The most effective setting for early diagnosis, 
regular screening, and lifestyle therapy is the primary care setting. There is a consensus among 
the most prominent organizations and the most notable researchers in the field, who 
acknowledge physical activity to be superior (Alberti et al., 2009; ACPM, 2009; American 
College of Sports Medicine [ACSM], 2006; Brewer, 2003; CDC, 2013; Eckel, Grundy, & 
Zimmet, 2005; IDF, 2006; Mottillo et al., 2010).  
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 The AHA/NHLBI (Grundy et al., 2005) maintained the ATP III 2002 criteria for 
metabolic syndrome due to the simplicity of use in a clinical setting and the advantage of 
avoiding emphasis of one characteristic. The Endocrine Society (Rosenzweig et al., 2008) 
recommended using the AHA/NHLBI definition, also based on simplicity and convenience in 
the outpatient primary care setting. The ATP III and AHA/NHLBI defined metabolic syndrome 
by the presence of (or treatment of) three or more of the following: abdominal obesity (waist 
circumference ≥ 35” in females, 40” in males), hypertension (≥ 130/85 or receiving 
antihypertensive therapy), elevated triglycerides (≥ 150 mg/dl or receiving anti-lipid therapy), 
reduced HDL (< 50 mg/dl in females, < 40 mg/dl in males), and an elevated fasting plasma 
glucose level (≥ 100 mg/dl; NCEP, 2002).  
The International Diabetes Foundation (IDF) (2006) guideline, like the AHA/NHLBI 
(2005) and Endocrine Society (2008), was based on the 2002 ATP III. The IDF (2006) definition 
differs in the inclusion of ethnicity-based waist circumference guidelines. These ethnicity-based 
waist circumference guidelines identify seven different national or ethnic groups. Europoid 
males are identified with abdominal obesity if waist circumference is > 94 cm, Europoid females 
> 80 cm. South Asian males are identified with abdominal obesity if waist circumference is > 90 
cm, South Asian females > 80 cm. Chinese and Japanese males and females are recommended to 
follow the South Asian recommendations. Sub-Saharan Africans and Eastern Mediterranean and 
Middle East populations are recommended to use Europoid recommendations. These 
recommendations may change in the future, as more specific data are available.  
 The Endocrine Society’s clinical guidelines further elaborated on managing metabolic 
risks associated with this syndrome (Rosenzweig et al., 2008). The Endocrine Society (2008) 
recommends screening for the main components of metabolic syndrome at regular intervals (at 
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least every 3 years) in individuals who have one or more risk factors but do not meet the 
established definitions of the syndrome. Waist circumference should be measured as a routine 
part of the clinical examination but does not replace measurement of weight or BMI. Individuals 
previously diagnosed with prediabetes should be screened for type II diabetes at 1–2-year 
intervals. Patients with metabolic syndrome should have 10-year risk assessment for coronary 
heart disease or cardiovascular disease done using the Framingham, Prospective Cardiovascular 
Munster scoring, or European SCORE algorithm.  
The most notable differences between the IDF (2006) and prior guidelines focus on 
weight management and weight loss goals during the first year of intervention. The IDF 
recommends five to ten percent body weight reduction whereas earlier AHA/NHLBI and ATP 
III guidelines recommended seven to ten percent reduction. This difference toward a more “user-
friendly” weight loss goal reflects the evidence that even a small amount of weight loss has 
clinical benefit. The Endocrine Society (Rosenzweig et al., 2008) panel concurs with the IDF 
(2006). They further suggest that weight loss, even in small increments, should continue beyond 
the first year until a determined weight loss goal is achieved. However, patients should 
understand that any amount of weight loss has benefit. 
Once diagnosed, patients with metabolic syndrome need to be managed steadfastly to 
reduce the risk of cardiovascular disease and type II diabetes (AHA/NHLBI, 2005; IDF, 2006). 
Lifestyle changes are first-line therapy and the focus of primary intervention. These changes 
should be led by an activity and dietary plan. Activity can lead to weight loss, and weight loss 
can lead to lean gain. Patients’ activity goals and weight loss goals will need to be adjusted over 
time and should be rechecked repeatedly. Secondary intervention, including drug therapy should 
be instituted when lifestyle modification is not sufficient to reach predefined goals and 
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individuals are at high risk for cardiovascular disease. Diet recommendations include reduced 
intake of saturated fat, transfat, and cholesterol. Patients should participate in moderate-intensity 
physical activity for at least 150 minutes a week, with 30 minutes of continuous or intermittent 
physical activity per day at least 5 days a week. A combination of aerobic and anaerobic exercise 
is most effective (Grundy et al., 2005). All of these recommendations are part of proper 
treatment, which can only be accomplished if adequate diagnosis is done.  
The Metabolic Syndrome Time Tool (ACPM, 2009) is a comprehensive guide for 
providers regarding metabolic syndrome, based on the ATP III definition. It 
provides rationales and information regarding the diagnosis, controversy, importance in clinical 
practice, lifestyle management, challenges in primary care, guide to the office visit, 
pharmacotherapy, and follow-up plan. The American College of Preventive Medicine also offers 
a Metabolic Syndrome Clinical Reference Page and A Guide For Patients to accompany the 
Time Tool. The Time Tool (ACPM, 2009) emphasizes what the purpose of identifying metabolic 
syndrome is and why treating it is important. The authors emphasize that metabolic syndrome is 
a syndrome, not a global risk predictor. Having metabolic syndrome doubles the risk for 
cardiovascular disease, which is five times the risk for type II diabetes alone. Metabolic 
syndrome identifies those at risk for health problems, especially cardiovascular disease and type 
II diabetes. It adds to cardiovascular disease risk beyond LDL cholesterol, emphasizes the 
detrimental effects of central fat accumulation, allows for quantification of lifestyle risk, and 
alerts that lifestyle modifications are needed immediately. Metabolic syndrome is vital in 
primary practice. 
Challenges for primary care for providers are to recognize metabolic syndrome, code for 
it, evaluate associated risk conditions, develop a medical plan, educate patients on why 
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recognition it is important, discuss needed lifestyle modifications and plan for achieving them. 
There is great need for an efficient approach to address all of this.  
The most logical critique of metabolic syndrome in primary care is that treatment of the 
syndrome is not different from treatment for each of its components (Kahn et al., 2005). 
However, after a thorough investigation of this syndrome, this DNP student has found that 
acknowledgement of metabolic syndrome as a comprehensive diagnosis is consistent with 
treating the patient as a whole person and in addressing the ‘big picture’, mirroring healthcare via 
the nursing model. A focus on primary care and prevention at primary, secondary, and tertiary 
levels is congruent with the current US healthcare initiatives of Healthy People 2020 (USDHHS, 
2014) and the Affordable Care Act. Also, if coded properly for metabolic syndrome, follow-up 
visits qualify for a more comprehensive visit, over more time, to assess and counsel.  
The Cardiometabolic Think Tank is a committee comprised of metabolic syndrome 
experts working to define new patient care models (Sperling et al., 2015). Consensus agreement 
of the think tank panel confirmed the definition of metabolic syndrome as a “complex 
pathophysiological state comprised of a cluster of clinically measured and typically unmeasured 
risk factors, is progressive in its course, and is associated with serious and extensive comorbidity 
but tends to be clinically under-recognized” (p. 3). The Think Tank panel reported that metabolic 
syndrome must be accurately identified as a diagnosis, and that ideally, those at risk for 
metabolic syndrome will be identified before the syndrome even develops. It is anticipated that 
since the 2015 Think Tank report was published, new guidelines for identification, diagnosis and 
managing of metabolic syndrome will be forthcoming. Until then, the AHA/NHLBI Guideline 
and the ACPM Time Tool, although older sources, are still the most current, widely accepted, 
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and best options available for comprehensive evidence based recommendations for screening, 
identification, coding, and management of metabolic syndrome in the primary care setting.  
Theoretical Framework 
 This project was guided by Program Theory (2005) and Lewin’s Theory of Change 
(1947). The Program Theory and Lewin’s Theory of Change were used to guide the design and 
implementation of the intervention. These models may be applied by clinical practice providers 
to present the opportunity of behavior change related to the screening and identification of 
metabolic syndrome, thereby improving patient health outcomes (Bickman, 1987; Issel, 2014; 
Lewin 1947; Rossi, Freeman, & Lipsey, 2004; Potvin, Gendron, Bilodeau, & Chabot, 2005). 
The Program Theory (2005) details how a health program will affect participants, provide 
guidance, and build a foundation for communication and action. Program Theory emphasizes the 
importance of involving team members and key stakeholders in the project to make the 
interventions more sustainable. For example, team members and key stakeholders signed 
contracts to signify their commitment to the project. Furthermore, the theory also takes into 
consideration health disparities and culturally bound health behaviors, which is important when 
addressing metabolic syndrome (Healthy People, 2010). Determination of need and preferences 
occurred through a needs assessment. Assessment took place at the population level with 
collecting and reviewing data. Educating and monitoring took place at the direct service level. 
Monitoring, the documentation of program performance to assess function, occurred at 
reassessment and follow-up. Education was performed throughout the intervention (Potvin et al., 
2005; Rossi, Lipsey, & Freeman (2004)). 
Lewin’s Theory of Change is a rational-linear change management model to guide 
changes. The three stages of Lewin’s Change Theory include unfreezing, transition, and 
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refreezing. Unfreezing is when a process, thought, behavior, mindset or knowledge is 
interrupted. The transition stage is when there is a change in the interrupted process, thought, 
behavior, mindset or knowledge. Refreezing is when the change becomes the new habit and 
therefore the norm. If refreezing does not occur, it is easy to fall back into previous habits and 
behaviors. Lewin’s Change Theory was used to identify barriers and facilitators to change, while 
providing a framework. The theory was selected based on its strengths including versatility, 
practicality, and simplicity. The transition phases included the opportunity to make adjustments 
to this organizational service utilization plan as the project progressed during the transition 
phase. Lewin’s Theory of Change helped to navigate short-term and long-term effects (Issel, 
2014; Lewin, 1947; Manchester et al., 2014; Shirley, 2013).  
In this project, the unfreezing was the identification of the gap in practice that patients are 
rarely diagnosed with metabolic syndrome. Unfreezing was identified during the pursuit of a 
different DNP project that would refer patients with metabolic syndrome to cardiopulmonary 
exercise testing to guide tailored activity/exercise plans. The moving and freezing stage was the 
presentation and delivery of the toolkit. This stage involved finding a way to seamlessly blend 
screening for metabolic syndrome into a provider’s routine. In the last stage, the refreezing 
occurs over time as providers adopt the new behavior. Based on provider feedback that will be 
discussed later, the intervention made an impression on the provider’s perception and validity of 
metabolic syndrome but did not change practice regarding use of ICD coding when metabolic 
syndrome was screened and identified. Refreezing may require repeated reinforcement and 
policy or procedural changes (Kritsonis, 2005; Sutherland, 2013).  
The Program Theory (Potvin et al., 2005) and Lewin’s Change Theory (Lewin, 1947; 
Shirley, 2013) complemented each other during this presentation and toolkit. For example, 
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Program Theory was beneficial during the transition stage of Change Theory in determining if 
improvements or changes in the delivery of the presentation and toolkit were needed.  
Toolkit 
Toolkit Objectives 
This DNP project was a presentation of a toolkit to address the lack of screening, 
identification, and coding of metabolic syndrome in primary care to an internal medicine clinic 
group in Massachusetts (Site A).  Upon invitation, this presentation was repeated at a family 
medicine clinic in Montana (Site B).  
The overarching goal of the presentation and toolkit was to increase provider awareness 
and knowledge of metabolic syndrome, including the most current and widely accepted 
definition, ICD coding and potential impact of using this diagnostic category for the practice. 
Providers and staff were provided with a practical and easy-to-apply toolkit for the primary care 
setting, including the presentation PowerPoint slides, Metabolic Syndrome Time Tool, ATP III 
checklist of inclusion criteria to meet the definition of metabolic syndrome, ACPM clinical 
reasoning of metabolic syndrome in the primary care setting, and ACPM patient education guide 
(see Appendix B). 
The DNP Student also wanted to gain an understanding of provider perception of 
metabolic syndrome because, despite the evidence available, there are not significant changes 
being made in primary care to include this ICD code and unrealized positive impacts on patient’s 
health are being missed.  
Target Population 
Overall, the population of interest was primary care providers caring for adult patients, 
eighteen years or older meeting the definition of metabolic syndrome or at risk of developing 
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metabolic syndrome. The setting in which the Site A intervention was implemented and 
evaluated was a large, for-profit internal medicine primary care clinic in Western Massachusetts. 
There are seven providers at the clinic, four physicians, two nurse practitioners, and one 
physician assistant. At the time of data analysis, 8,665 patients received care at the clinic and 23 
patients were coded with metabolic syndrome. Site B is a small, rural, non-profit family 
medicine clinic in Montana. There are two physicians and one physician assistant providing care 
to an estimated 2,000 patients. At the time of data analysis, no patients at Site B were coded with 
metabolic syndrome.  
The presentation and toolkit was offered to the entire staff at Sites A and B, but the focus 
was on primary care providers. The majority of providers reported familiarity with metabolic 
syndrome but not regular use in practice. Site A was selected for the presentation and toolkit 
delivery because the expected rates of metabolic syndrome were based on national and global 
estimates of the prevalence of metabolic syndrome and the limited availability of individual 
metabolic syndrome characteristics for the states of Massachusetts and Montana. It was assumed 
by the DNP Student that both sites should have approximately one-third of their adult population 
coded with metabolic syndrome.  
Presentation of Toolkit 
The PowerPoint and verbal presentation were provided on-site to healthcare staff, 
including providers (Nurse Practitioner [NP], Physician Assistant [PA], Doctor of Medicine 
[MD] and nurses [Registered Nurse and Licensed Practical Nurse]). The presentation was based 
on the above review of literature and the 2009 Metabolic Syndrome Time Tool from the ACPM. 
The intervention also included a toolkit based on the Time Tool and emphasized the inclusion of 
metabolic syndrome in patient care, assessment, treatment planning, and follow-up. Key 
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elements also included definition, impact, risk, and diagnosis. The use of metabolic syndrome in 
prevention was accentuated. Critical elements included the definition of metabolic syndrome and 
urgency and impact of lifestyle changes.  
This project was not a research study and did not include practice patients or individual 
patient data. Adherence to site policy and procedures were followed. Patient records were 
HIPAA protected and office personnel retrieved needed health related information for the DNP 
Student. Provider survey responses were kept anonymous. Risks identified for human subjects 
from this intervention were minimal. Per DNP Project Committee, IRB approval was not needed 
(U.S. Department of Health and Human Services [USDHHS], 2009).  
Site A presentation and administration of the toolkit occurred in January 2016 with 
follow-up in February 2016. The Site B presentation and toolkit delivery occurred in February 
2016 with follow-up in March 2016. Regular e-mail communication occurred with the Site A 
mentor leading up to the intervention and through follow-up. The Site B mentor was established 
at the time of the intervention and assisted with data gathering and follow-up. Site A providers 
were notified of the presentation and timeline of communication one month prior to the 
presentation. Only one provider corresponded prior to the presentation via e-mail, expressing 
skepticism over the validity of metabolic syndrome. Prior to the presentation, a pre-presentation 
questionnaire was submitted to the providers. At site B, the DNP student was invited to present, 
and the providers were notified by e-mail three days in advance. Clinic nurses were provided 
with a short four-question survey assessing their readiness to participate in screening for 
metabolic syndrome. A follow-up e-mail was sent to providers at Week 2. Content included 
metabolic syndrome facts and information about the number of patients seen at Site A between 
the ages of 45 and 65 who had diagnoses such as hypertension, type II diabetes, obesity, and high 
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cholesterol. At Site A and Site B, the DNP student mentors generously retrieved needed 
information for the DNP Student. The mentors gathered data for pre-intervention and follow-up 
metabolic syndrome population data.  
In order to achieve success of the DNP project, key stakeholders were engaged (see 
signed Stakeholder Agreements in Appendix A). Stakeholders included the four physician 
owners of Site A, the clinic manager, and DNP Student Mentor. Stakeholders did not sign 
agreements at Site B due to the process of inviting the DNP Student to present. The DNP at the 
internal medicine clinic (Site A) was the primary contact, mentor, and facilitator through the 
project. This individual worked closely with the DNP student throughout the duration of the 
project. Stakeholders also included the RN who assisted in gathering clinic data and all providers 
who participated. Site B included two mentors, a physician and RN who assisted in data 
collection and follow-up.  
Outcomes 
The outcomes from the presentation and toolkit were numerous. The presentation and 
toolkit were well attended and well received. Additional information was obtained in surveys 
prior to the presentation and after the presentation. At Site A and B, providers were surveyed 
through pre-presentation, post-presentation, and follow-up surveys. Nurses were given a nurse 
readiness survey. All survey responses are available in Appendix C. At Site A, six out of seven 
providers (NP, PA, MD) completed the pre-presentation survey. At Site B, two out of three 
providers (PA, MD) completed the pre-presentation survey.  
The follow-up was a two-part process. The providers from each site were sent an online 
survey through SurveyMonkey to assess the changes in their knowledge, perception, and 
application of metabolic syndrome. At Site A, six out of seven providers completed the pre-
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presentation survey, five out of seven the post-presentation survey, and five out of seven the 
follow-up survey. Three out of three nurses completed the nurse readiness survey. At Site B, two 
out of three providers completed the pre-presentation survey, one out of three the post-
presentation survey, and two out of three the follow-up survey. Three out of three nurses 
completed the nurse readiness survey. Those who did not complete any survey leading up to 
and/or the final follow-up survey are considered lost to follow-up at this time, but any partial 
completion of the surveys still provided valuable information.  
More specific feedback was collected from Site A. There was also a higher response rate 
at Site A, as five out of seven or 71% of providers from Site A completed the follow-up survey 
compared to two out of three or 66% of providers from Site B who completed the follow-up 
survey.  
 Prior to the presentation, 23/8665 patients at Site A were coded with metabolic 
syndrome. After the presentation and distribution of the toolkit, 25/8665 patients were coded 
with metabolic syndrome. At Site B, no patients were coded with metabolic syndrome before or 
after the DNP Project. At Site A, efforts were made by the clinic to look into insurance 
reimbursement as well as electronic medical record (EMR) alerts. At the time of write-up, no 
changes regarding insurance reimbursement and EMR alerts had been made. However, the DNP 
student was reassured that these kinds of changes happen slowly.   
The DNP student also investigated insurance reimbursement and discovered that 
reimbursement information is quite limited. Requests were made repeatedly to three insurance 
companies, but no responses were provided. Based on this experience, it is difficult to access any 
information from insurers. An office NP or MD who is credentialed by the insurers would best 
accomplish this investigation. Further lobbying efforts should be made with insurance companies 
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to properly reimburse for these preventative visits, whether addressing primary, secondary, or 
tertiary care. 
Feedback from the survey included not only information on patient care but also 
anecdotal feedback regarding personal changes of the providers and staff who attended the 
conference. While the numbers of patients diagnosed with metabolic syndrome did not 
significantly change, the common response implied that the impact of lifestyle choices and 
changes along with prevention were valuable tools in considering patient counseling and 
treatment plans.  
There were many positive results from the collection of surveys. Provider answers spoke 
to the efficacy of the intervention, benefits to patient care, value of metabolic syndrome, and 
future patient care changes. Nurses overwhelmingly responded positively in willingness to 
participate in patient care. Of note, providers responded that identification and treatment of 
metabolic syndrome is useful in preventing atherosclerosis. Providers reported that the 
presentation and toolkit helped them realize that discussing metabolic syndrome with patients 
may help motivate them to be successful in lifestyle changes, and realize that lifestyle changes 
are important. Providers also suggested they will engage in future patient education and 
motivation to achieve patient lifestyle changes and prevention of metabolic syndrome.   
All of the providers at Site A responded that the presentation and toolkit affected their 
approach to metabolic syndrome. The intervention made them aware of the importance of 
lifestyle changes and impact that patient education may have. Three Site A providers reported a 
change in their practice regarding metabolic syndrome, specifying that they tried to recognize the 
multiple symptoms of metabolic syndrome and to help at risk patients. Four Site A providers 
reported counseling more patients on metabolic syndrome. Four providers also reported they felt 
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that changing their practice was beneficial. Site B providers did not indicate a change in practice. 
They did show a perceived value in the identification and treatment of metabolic syndrome in 
atherosclerosis prevention. They also reported the definition of metabolic syndrome was well 
defined.  
Analysis of the nurse readiness survey shows that 100% of the nurses reported they 
would be willing to assist in screening patients. Additionally, 100% of nurses identified that a 
checklist and space for documentation would support them in screening patients. The criteria 
table from the AHA/NHLBI found in Appendix B Toolkit Contents could be used for nurse 
screening. Documentation would likely need to be individualized on a site-by-site basis, 
dependent on the use of electronic health record.  
Based on informal expressions such as e-mail and questions and statements prior to and 
after the presentation, the DNP student had the impression that the providers overreported their 
use of metabolic syndrome. This was also supported in survey responses. For example, there was 
a noted discrepancy between the number of providers that reported using metabolic syndrome 
codes and what was found on the pre-intervention assessment of charts. Based on provider 
answers, there has been some self-reporting bias, particularly “often” or “frequently” as the EMR 
statistics do not support this. Also, no provider definitions of metabolic syndrome specified 
inclusion criteria, and the preferred guideline was not identified.  
Self-reporting bias was noted when providers were asked if they currently use ICD-10 
coding for patients diagnosed with metabolic syndrome. Three providers reported coding habits 
ranging from rarely to frequently. This shows self-reporting bias because if rare, often, or 
frequent ICD 10 coding of metabolic syndrome was used, the number of patients coded with 
metabolic syndrome would be greater than 23 out of 8,665.  
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Additional self-reporting bias was noted because providers answered questions based on 
previous questions that were dependent on yes or no questions.  Only three providers should 
have responded questions 2, 3, &4 in this survey. This observation is also relevant to question 3 
and question 4. This also reflects self-reporting bias because there was little change to the 
number of patients diagnosed with metabolic syndrome, as seen below. However, it is noted that 
the question style may have been confusing to the two providers who answered the irrelevant 
questions.  
When asked if the providers screen for metabolic syndrome, one provider reported rare 
screening and the other reported often screening. This shows self-reporting bias because no 
patients were coded with metabolic syndrome, therefore never screening would have been a 
better response.  
To further support suspected over-reporting of documentation, in April 2015, data was 
collected on some of the characteristics of metabolic syndrome. The codes listed are ICD-9 
because ICD-9 was in use at the clinic in April 2015. This is just a snapshot for a limited adult 
population. There were 1,395 patients age 45–65 with 401 (hypertension). There were 1,271 
patients age 45–65 with 278 (obesity). There were 341 patients age 45–65 with 250.0 (diabetes 
without complications). Imagine the number of patients who also have low HDL, high LDL, 
prehypertension, elevated fasting plasma glucose, and abdominal obesity or are maybe just 
overweight. The numbers are staggering.  
In summary, key results of the project included the following: 
1. An educational intervention PowerPoint, verbal presentation, and metabolic 
syndrome tool kit were presented to two clinical sites in January and February 2016.  
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2. After the metabolic syndrome educational intervention, participants reported 
increased knowledge of metabolic syndrome.  
3. After 1 month, participants reported a change in their clinical approach to patients 
with metabolic syndrome and a shift in their focus to prevention and lifestyle.  
4. Yet, after 1 month, the number of patients coded with metabolic syndrome did not 
increase.  
5. Self-reporting bias was noted in provider survey responses. 
6. In light of #4 and #5 above, regarding the persistent clinical inertia of providers and 
self-reporting bias, further investigation is needed. 
Discussion 
Benefits of Toolkit  
 Benefits of the toolkit are numerous. For example, even though the guidelines and the 
Time Tool are a few years old, they are still the most evidence-based information available.  The 
organization of the Time Tool is clear and easy to understand, as is the toolkit. The PowerPoint 
succinctly communicates important information, the Time Tool provides relevant practice 
knowledge, the clinical reference provides in-depth information, the patient guide is appropriate 
for adults with metabolic syndrome, and the checklist is straightforward. Practical rationales are 
also present throughout, to help providers see the value of these interventions despite the 
additional time and resources needed.  
 The Toolkit also emphasizes the benefits of prevention and patient education. This is 
valuable because the lifestyle changes are first-line interventions, due to safety and efficacy.  
Finally, the toolkit communicates that using metabolic syndrome coding would be more effective 
office visits, more comprehensive follow-up visits, more time to spend on counseling.  
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Limitations 
In the survey, providers reported limitations related to time for patient visits and 
resources to support patients, as well as financial reimbursement. Some providers demonstrated 
skepticism by questioning if the treatment for metabolic syndrome was really that different from 
each individual component. There was also the appearance of self-reporting bias. Providers 
commented on time constraints being major barriers for addressing metabolic syndrome as well 
as screening and coding. One provider at Site B stated that they did not think the diagnosis of 
metabolic syndrome would change treatment in the post-presentation survey.  
Self-reporting bias was mostly speculated on questions regarding the use of metabolic 
syndrome coding in patient care. For example, three Site A providers reported Rarely, Often, or 
Frequent coding of patients diagnosed with metabolic syndrome even though the number of 
patients coded with metabolic syndrome was very low. Another example is in the Site B follow-
up survey. Providers there also reported, post-presentation, that they Sometimes code patients 
with metabolic syndrome, but in the pre-presentation survey, they reported Rarely. However, 
there was no change in coding of patients with metabolic syndrome on follow-up 
communications with sites for population analysis. At Site A and B, some providers answered 
questions on the follow-up survey that were not applicable based on the question and some of 
these follow-up answers were contradictory. For example, in the follow-up survey providers 
were instructed to answer questions two through question four only if they answered yes to 
question on. Based on this, future consideration will be given to instruction wording, as this may 
have been confusing to providers.  
The higher response rate at Site A is of interest to the DNP Student because Site A was 
identified by the DNP Student as having a gap in practice and the DNP Student then obtained 
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permission to administer the presentation and toolkit. At Site B, the DNP Student was 
completing clinical work for a different course. The DNP student advisor and mentor voluntarily 
invited the DNP Student to present the project. 
These surveys focused on qualitative data, which can be challenging to validate. 
However, these are the data that are needed. Evidence and statistics are already present to show 
the prevalence and impact of metabolic syndrome and benefits for positive patient outcomes if 
recognized early and treated. Yet, even with clear percentages and statistics, metabolic syndrome 
is not being used as it should be as diagnostic code in primary care.  
Future Recommendations 
Many researchers are focusing on all of the impacts of metabolic syndrome. It is well 
known that the impact is far beyond just the current five characteristics used to diagnose and 
identify metabolic syndrome. Other impacts include carbohydrate intolerance, endothelial 
dysfunction, increased coagulation, decreased fibrinolysis, microalbuminuria, lipid disturbances, 
pro-thrombic factors, and pro-inflammatory factors. More investigation is needed to address the 
identification and coding of metabolic syndrome in primary care. 
The CardioMetabolic Health Alliance Think Tank 
(https://www.cardiometabolichealth.org/cardiometabolic-think-tank-releases-new-patient-care-
model-for-metabolic-syndrome.html) and others are working to create a new patient diagnosis 
and care model. This is valuable for future improvements toward better screening, identification, 
diagnosis and management of patients with metabolic syndrome and to address barriers providers 
face in implementing the evidence-based practice. The DNP student agrees with the Think Tank 
report in that diagnosis and team-based care coordination, use of social media, and 
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considerations for reimbursement of ICD 10 coding for metabolic syndrome, in particular, 
should be considered.   
It is the DNP Student’s opinion that screening, identification, and treatment of metabolic 
syndrome will not be commonplace until there is published common patient visit, monitoring, 
and documentation standards specifically for metabolic syndrome, as well as insurance 
reimbursement similar to diabetes. For example, diabetes patient care (ADA, 2014) includes a 
history and physical performed two or three times a year, an annual foot exam, and laboratory 
A1c testing every three or six months. There is also annual laboratory testing of a fasting lipid 
profile, liver function tests, urine albumin secretion, and serum creatinine.  
Conclusion 
The five characteristics of metabolic syndrome are recognized by many healthcare 
organizations such as ATP III, AHA, NHLBI, IDF, Endocrine Society, and many others. Use of 
the ICD 10 code for metabolic syndrome can identify patients who are not being treated 
aggressively enough and allow for preventive healthcare to slow or stop worsening health.  
The purpose of this DNP project was to deliver a verbal presentation and PowerPoint, as 
well as a toolkit for practice, with the intent of increasing providers’ knowledge and 
identification of adult patients with metabolic syndrome in the primary care setting. The 
presentation and toolkit was developed with Program Theory and Lewin’s Theory of Change, 
ACPM Time Tool, and review of literature. Based on intervention pre-, post-, and follow-up 
surveys, providers do feel that metabolic syndrome has value, which is supported by evidence-
based guidelines and research. The majority of providers found that a toolkit addressing 
metabolic syndrome in primary care affected their approach to metabolic syndrome. Metabolic 
syndrome education can change the way providers discuss lifestyle changes and need for 
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prevention with patients. Additionally, nurses are also willing to participate in patient metabolic 
screening.  
Information collected in these surveys does echo available data. Metabolic syndrome is 
prevalent, but few providers identify or address the constellation of problems, preferring to 
address each component individually. However, the providers also recognize the benefits of 
using metabolic syndrome to emphasize prevention and lifestyle changes. It is the opinion of the 
DNP student and others that metabolic syndrome does not fit easily into the current routine and 
expectations of patient care that are dictated by the status quo and requirements from 
organizations such as insurance companies, Medicare, and Medicaid. The responses from 
providers begin to paint a clearer picture of what is needed to support the use of metabolic 
syndrome as a diagnostic category.  
The Metabolic Syndrome Time Tool from the American College of Preventive Medicine 
is evidence-based, and its content and information are valuable for all providers until newer 
guidelines and information become available. Addressing metabolic syndrome as an aggregate or 
constellation versus individual problems promotes more effective and efficient identification, 
diagnosis and care as well as a clearer emphasis on the need for lifestyle changes. In today’s 
healthcare system, value is increasingly placed on prevention, as evidence is available on health 
outcomes and political systems, such as the Affordable Care Act and Healthy People 2020. Yet, 
if identification and diagnosis is not made first, prevention efforts are under realized and 
incomplete. 
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Appendix C 
Site A SurveyMonkey Surveys and Results 
 



































Q8 What is first line treatment of metabolic
syndrome?
Answered: 6 Skipped: 0
# Responses Date
1 weight loss 1/18/2016 9:31 AM
2 lifestyle choieces 1/18/2016 8:48 AM
3 Diet 1/18/2016 8:35 AM
4 Lifestyle modifications 1/18/2016 8:25 AM
5 weight loss 1/18/2016 7:09 AM
6 Lifestyle change diet exercise 1/13/2016 5:08 AM
8 / 10
Sadie Russell Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey





Q9 What is the goal of treating metabolic
syndrome?
Answered: 6 Skipped: 0
# Responses Date
1 decrease bmi 1/18/2016 9:31 AM
2 decreased weight, stable glucose, htn controlled 1/18/2016 8:49 AM
3 Control at, bp, glucose, lipids 1/18/2016 8:36 AM
4 to control the multiple factors that go into increasing risk for cardiac issues and preventing stroke such as controlling
DM, HTN, Hyperlipidemia, etc.
1/18/2016 8:26 AM
5 improve all parameters 1/18/2016 7:10 AM
6 Reduce the progression of sx 1/13/2016 5:09 AM
9 / 10
Sadie Russell Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey













Q10 What is your professional role?
Answered: 6 Skipped: 0
Total 6
# Other (please specify) Date





















Sadie Russell Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey










Q2 Do you feel that identification and
treatment of metabolic syndrome is useful
in preventing atherosclerosis?
Answered: 5 Skipped: 0
# Responses Date
1 Yes 1/18/2016 5:20 PM
2 possibly 1/18/2016 4:08 PM
3 yes 1/18/2016 2:57 PM
4 Yes, I discuss lifestyle modifications with the majority of my patients and in the future I hope to have a discussion with
patients about the specifics of metabolic syndrome.
1/18/2016 2:15 PM
5 Yes 1/18/2016 2:08 PM
2 / 4
Post-presentation Survey SurveyMonkey
































Q1 Have you changed your practice over
the past month regarding metabolic
syndrome?
Answered: 5 Skipped: 0
Total 5
# If yes, why? If no, why? Date
1 to help recognize at risk patients 3/23/2016 12:20 PM
2 Tried to recognize the multiple sx that make metabolic syndro 2/19/2016 2:33 AM
Yes
No





Follow-up Survey (Metabolic Syndrome) SurveyMonkey







Q2 If yes to question 1, have you
coded more patients with metabolic
syndrome?









Follow-up Survey (Metabolic Syndrome) SurveyMonkey







Q3 If yes to question 1, have you counseled
more patients on metabolic syndrome? 









Follow-up Survey (Metabolic Syndrome) SurveyMonkey







Q4 If yes to question 1, do you feel
changing your practice has been
beneficial?









Follow-up Survey (Metabolic Syndrome) SurveyMonkey





Q5 Out of all your patients that you estimate
have metabolic syndrome, what percentage
of patients do you address metabolic
syndrome with during the patient visit? 
Answered: 5 Skipped: 0
# Responses Date
1 I have always addressed these issues but have never coded for it so although I have coded for metabolic syndrome a
few more times in the past month I have not changed how many patients I speak to about it because I have always
had these discussions with my patients.
3/23/2016 12:22 PM
2 ? 3/23/2016 10:19 AM
3 all of them 2/20/2016 6:15 AM
4 The problem here is that we only have time to address it during a physical exam. I only have up to four physical exams
scheduled in a visit and of those the percentage that may qualify for met metabolic syndrome
2/19/2016 2:34 AM
5 50 2/18/2016 7:04 PM
5 / 10
Follow-up Survey (Metabolic Syndrome) SurveyMonkey










Q6 Do you screen patients for metabolic
syndrome?
Answered: 5 Skipped: 0
Total 5
# Comment? Please share! Date





(25 - 50% of...
3 = Often (50
- 75% of my...
4 = Frequently
(100% of my...
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Answer Choices Responses
0 = Never
1 = Rarely (<25% of my patient population)
2 = Sometimes (25 - 50% of my patient population)
3 = Often (50 - 75% of my patient population)
4 = Frequently (100% of my patient population)
6 / 10
Follow-up Survey (Metabolic Syndrome) SurveyMonkey










Q7 Do you use the ICD 10 (or 9) code for
patients diagnosed with metabolic
syndrome?
Answered: 5 Skipped: 0
Total 5
# Comment? Please share! Date





(25 - 50% of...
3 = Often (50
- 75% of my...
4 = Frequently
(100% of my...
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Answer Choices Responses
0 = Never
1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)
2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)
3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)
4 = Frequently (100% of my patient population)
7 / 10
Follow-up Survey (Metabolic Syndrome) SurveyMonkey










Q8 Do you counsel patients on metabolic
syndrome?
Answered: 5 Skipped: 0
Total 5
# Comment? Please share! Date





(25 - 50% of...
3 = Often (50
- 75% of my...
4 = Frequently
(100% of my...
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Answer Choices Responses
0 = Never
1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)
2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)
3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)
4 = Frequently (100% of my patient population)
8 / 10
Follow-up Survey (Metabolic Syndrome) SurveyMonkey










Q9 Does metabolic syndrome affect your
treatment plan for individual patients?
Answered: 5 Skipped: 0
Total 5
# Comment? Please share! Date





(25 - 50% of...
3 = Often (50
- 75% of my...
4 = Frequently
(100% of my...
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Answer Choices Responses
0 = Never
1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)
2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)
3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)
4 = Frequently (100% of my patient population)
9 / 10
Follow-up Survey (Metabolic Syndrome) SurveyMonkey













Q10 What is your professional role?
Answered: 5 Skipped: 0
Total 5
# Other (please specify) Date





















Follow-up Survey (Metabolic Syndrome) SurveyMonkey
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Q1 Do you screen patients for metabolic
syndrome?
Answered: 2 Skipped: 0
Total 2
# Comment? Please share! Date





(25 - 50% of...
3 = Often (50
- 75% of my...
4 = Frequently
(100% of my...
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Answer Choices Responses
0 = Never
1 = Rarely (<25% of my patient population)
2 = Sometimes (25 - 50% of my patient population)
3 = Often (50 - 75% of my patient population)
4 = Frequently (100% of my patient population)
1 / 10
Site B Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey










Q2 Do you use the ICD 10 (or 9) code for
patients diagnosed with metabolic
syndrome?
Answered: 2 Skipped: 0
Total 2
# Comment? Please share! Date





(25 - 50% of...
3 = Often (50
- 75% of my...
4 = Frequently
(100% of my...
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Answer Choices Responses
0 = Never
1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)
2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)
3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)
4 = Frequently (100% of my patient population)
2 / 10
Site B Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey










Q3 Do you counsel patients on metabolic
syndrome?
Answered: 2 Skipped: 0
Total 2
# Comment? Please share! Date





(25 - 50% of...
3 = Often (50
- 75% of my...
4 = Frequently
(100% of my...
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Answer Choices Responses
0 = Never
1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)
2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)
3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)
4 = Frequently (100% of my patient population)
3 / 10
Site B Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey










Q4 Does metabolic syndrome affect your
treatment plan for individual patients?
Answered: 2 Skipped: 0
Total 2
# Comment? Please share! Date





(25 - 50% of...
3 = Often (50
- 75% of my...
4 = Frequently
(100% of my...
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Answer Choices Responses
0 = Never
1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)
2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)
3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)
4 = Frequently (100% of my patient population)
4 / 10
Site B Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey





Q5 Describe or define metabolic syndrome.
Answered: 2 Skipped: 0
# Responses Date
1 specific criteria elevated triglycerides, qwaist size increased, fasting glucose elevated, bp elevated. cholestero;l
elevated and low hdl
2/22/2016 12:46 PM
2 3 of 5 criteria 2/22/2016 12:37 PM
5 / 10
Site B Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey
IDENTIFYING PATIENTS WITH METABOLIC SYNDROME 90 
 
Q6 What is the preferred guideline to follow
for metabolic syndrome?
Answered: 2 Skipped: 0
# Responses Date
1 follow labs and recheck 6 months 2/22/2016 12:46 PM
2 lidestyle changes and drugs 2/22/2016 12:37 PM
6 / 10
Site B Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey
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Q7 What are the five characteristics of
metabolic syndrome?
Answered: 2 Skipped: 0
# Responses Date
1 see previous answer 2/22/2016 12:46 PM
2 hypertension, elevated glucose, hypertriglyceridemia, abd obesity 2/22/2016 12:37 PM
7 / 10
Site B Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey





Q8 What is first line treatment of metabolic
syndrome?
Answered: 2 Skipped: 0
# Responses Date
1 diet exercise wt loss 2/22/2016 12:46 PM
2 lifestyle modification 2/22/2016 12:38 PM
8 / 10
Site B Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey





Q9 What is the goal of treating metabolic
syndrome?
Answered: 2 Skipped: 0
# Responses Date
1 wt loss and reduction of risk factors 2/22/2016 12:47 PM
2 reduce risk of morbidity 2/22/2016 12:38 PM
9 / 10
Site B Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey













Q10 What is your professional role?
Answered: 2 Skipped: 0
Total 2
# Other (please specify) Date





















Site B Pre-Presentation Questionnaire (Metabolic Syndrome) SurveyMonkey





Q1 Do you feel the definition of metabolic
syndrome is well defined?
Answered: 1 Skipped: 0
# Responses Date
1 yes 2/24/2016 7:03 AM
1 / 4
Site B Clinic Post-presentation Survey SurveyMonkey





Q2 Do you feel that identification and
treatment of metabolic syndrome is useful
in preventing atherosclerosis?
Answered: 1 Skipped: 0
# Responses Date
1 yes 2/24/2016 7:03 AM
2 / 4
Site B Clinic Post-presentation Survey SurveyMonkey





Q3 Do you feel that the diagnosis of
metabolic syndrome will change treatment
in individual patients?
Answered: 1 Skipped: 0
# Responses Date
1 no 2/24/2016 7:03 AM
3 / 4
Site B Clinic Post-presentation Survey SurveyMonkey





Q4 Does this educational intervention affect
your approach to metabolic syndrome?
Answered: 0 Skipped: 1
# Responses Date
 There are no responses.  
4 / 4
Site B Clinic Post-presentation Survey SurveyMonkey







Q1 Have you changed your practice over
the past month regarding metabolic
syndrome?
Answered: 2 Skipped: 0
Total 2
# If yes, why? If no, why? Date
 There are no responses.  
Yes
No





Site B Follow-up Survey (Metabolic Syndrome) SurveyMonkey







Q2 If yes to question 1, have you
coded more patients with metabolic
syndrome?









Site B Follow-up Survey (Metabolic Syndrome) SurveyMonkey







Q3 If yes to question 1, have you counseled
more patients on metabolic syndrome? 









Site B Follow-up Survey (Metabolic Syndrome) SurveyMonkey







Q4 If yes to question 1, do you feel
changing your practice has been
beneficial?









Site B Follow-up Survey (Metabolic Syndrome) SurveyMonkey





Q5 Out of all your patients that you estimate
have metabolic syndrome, what percentage
of patients do you address metabolic
syndrome with during the patient visit? 
Answered: 2 Skipped: 0
# Responses Date
1 10 3/23/2016 3:52 PM
2 unknown 3/23/2016 10:41 AM
5 / 10
Site B Follow-up Survey (Metabolic Syndrome) SurveyMonkey










Q6 Do you screen patients for metabolic
syndrome?
Answered: 2 Skipped: 0
Total 2
# Comment? Please share! Date





(25 - 50% of...
3 = Often (50
- 75% of my...
4 = Frequently
(100% of my...
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Answer Choices Responses
0 = Never
1 = Rarely (<25% of my patient population)
2 = Sometimes (25 - 50% of my patient population)
3 = Often (50 - 75% of my patient population)
4 = Frequently (100% of my patient population)
6 / 10
Site B Follow-up Survey (Metabolic Syndrome) SurveyMonkey










Q7 Do you use the ICD 10 (or 9) code for
patients diagnosed with metabolic
syndrome?
Answered: 2 Skipped: 0
Total 2
# Comment? Please share! Date





(25 - 50% of...
3 = Often (50
- 75% of my...
4 = Frequently
(100% of my...
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Answer Choices Responses
0 = Never
1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)
2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)
3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)
4 = Frequently (100% of my patient population)
7 / 10
Site B Follow-up Survey (Metabolic Syndrome) SurveyMonkey










Q8 Do you counsel patients on metabolic
syndrome?
Answered: 2 Skipped: 0
Total 2
# Comment? Please share! Date





(25 - 50% of...
3 = Often (50
- 75% of my...
4 = Frequently
(100% of my...
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Answer Choices Responses
0 = Never
1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)
2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)
3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)
4 = Frequently (100% of my patient population)
8 / 10
Site B Follow-up Survey (Metabolic Syndrome) SurveyMonkey










Q9 Does metabolic syndrome affect your
treatment plan for individual patients?
Answered: 2 Skipped: 0
Total 2
# Comment? Please share! Date





(25 - 50% of...
3 = Often (50
- 75% of my...
4 = Frequently
(100% of my...
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Answer Choices Responses
0 = Never
1 = Rarely (<25% of my patients diagnosed with metabolic syndrome)
2 = Sometimes (25 - 50% of my patients diagnosed with metabolic syndrome)
3 = Often (50 - 75% of my patients diagnosed with metabolic syndrome)
4 = Frequently (100% of my patient population)
9 / 10
Site B Follow-up Survey (Metabolic Syndrome) SurveyMonkey













Q10 What is your professional role?
Answered: 2 Skipped: 0
Total 2
# Other (please specify) Date





















Site B Follow-up Survey (Metabolic Syndrome) SurveyMonkey





Q1 Would you be willing to assist in
screening patients for metabolic syndrome
as you are rooming them?
Answered: 3 Skipped: 0
# Responses Date
1 yes 2/24/2016 8:45 AM
2 yes 2/23/2016 4:11 PM
3 yes 2/23/2016 12:55 PM
1 / 3
Site B Clinic Nurse Survey SurveyMonkey
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Q2 If not, why?
Answered: 1 Skipped: 2
# Responses Date
1 na 2/23/2016 12:55 PM
2 / 3
Site B Clinic Nurse Survey SurveyMonkey




Q3 What would support you to complete
this additional patient screening?
Answered: 3 Skipped: 0
# Responses Date
1 would need appropriate place for screening and documentation in cerner 2/24/2016 8:46 AM
2 Screens on the Ehr for documenting the areas necessary to diagnose Metabolic syndrome. Triggers to do waist
measuremnts etc.
2/23/2016 4:15 PM
3 a short template of questions 2/23/2016 12:55 PM
3 / 3
Site B Clinic Nurse Survey SurveyMonkey
